RxDoctor Payments Data

Ajay Chander, MD

Cardiovascular Disease · Lincoln, NENPI 1598880098

Payments from drug & device makers

$670in general payments, 2019–2025

Across 50 payments — averaging $13.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$160
  • Amgen$142
  • Pfizer$116
  • Sanofi-aventis U.S. LLC$97
  • Johnson & Johnson$56
  • Amarin Pharma, Inc.$26
  • plus $74 from 5 others

What the payments were for

  • Food & beverage$670100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$670 in reported general payments places this provider in the 20th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska

Medicare billing

Part B allowed, 2024
$196,977
Medicare patients
521
Services billed
2,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban234$220,749
EntrestoSacubitril/Valsartan116$115,153
Repatha SureclickEvolocumab99$89,795
XareltoRivaroxaban46$43,551
Repatha PushtronexEvolocumab30$29,778
FarxigaDapagliflozin Propanediol18$18,561
Praluent PenAlirocumab17$17,660
Repatha SyringeEvolocumab11$7,098
Nebivolol Hcl130$6,910
BrilintaTicagrelor11$4,723
Diltiazem 12hr ErDiltiazem Hcl12$3,376
Metoprolol Succinate176$2,756
Atorvastatin Calcium204$2,387
Amiodarone Hcl79$2,375
Olmesartan Medoxomil112$2,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$116$220,749234 claims
NovartisEntresto$160$115,153116 claims
Johnson & JohnsonXarelto$56$43,55146 claims
Boehringer IngelheimPradaxa$14$2,04511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 97 cardiovascular disease providers in Nebraska.

Other cardiovascular disease in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →